Cargando…
Scalable Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral Purification Strategy
Disease-specific induced pluripotent stem (iPS) cells can be generated from patients and differentiated into functional cardiomyocytes for characterization of the disease and for drug screening. In order to obtain pure cardiomyocytes for automated electrophysiological investigation, we here report a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470242/ https://www.ncbi.nlm.nih.gov/pubmed/26237021 http://dx.doi.org/10.3390/jcm4010102 |
_version_ | 1782376737042071552 |
---|---|
author | Friedrichs, Stephanie Malan, Daniela Voss, Yvonne Sasse, Philipp |
author_facet | Friedrichs, Stephanie Malan, Daniela Voss, Yvonne Sasse, Philipp |
author_sort | Friedrichs, Stephanie |
collection | PubMed |
description | Disease-specific induced pluripotent stem (iPS) cells can be generated from patients and differentiated into functional cardiomyocytes for characterization of the disease and for drug screening. In order to obtain pure cardiomyocytes for automated electrophysiological investigation, we here report a novel non-clonal purification strategy by using lentiviral gene transfer of a puromycin resistance gene under the control of a cardiac-specific promoter. We have applied this method to our previous reported wild-type and long QT syndrome 3 (LQTS 3)-specific mouse iPS cells and obtained a pure cardiomyocyte population. These cells were investigated by action potential analysis with manual and automatic planar patch clamp technologies, as well as by recording extracellular field potentials using a microelectrode array system. Action potentials and field potentials showed the characteristic prolongation at low heart rates in LQTS 3-specific, but not in wild-type iPS cell-derived cardiomyocytes. Hence, LQTS 3-specific cardiomyocytes can be purified from iPS cells with a lentiviral strategy, maintain the hallmarks of the LQTS 3 disease and can be used for automated electrophysiological characterization and drug screening. |
format | Online Article Text |
id | pubmed-4470242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-44702422015-07-28 Scalable Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral Purification Strategy Friedrichs, Stephanie Malan, Daniela Voss, Yvonne Sasse, Philipp J Clin Med Article Disease-specific induced pluripotent stem (iPS) cells can be generated from patients and differentiated into functional cardiomyocytes for characterization of the disease and for drug screening. In order to obtain pure cardiomyocytes for automated electrophysiological investigation, we here report a novel non-clonal purification strategy by using lentiviral gene transfer of a puromycin resistance gene under the control of a cardiac-specific promoter. We have applied this method to our previous reported wild-type and long QT syndrome 3 (LQTS 3)-specific mouse iPS cells and obtained a pure cardiomyocyte population. These cells were investigated by action potential analysis with manual and automatic planar patch clamp technologies, as well as by recording extracellular field potentials using a microelectrode array system. Action potentials and field potentials showed the characteristic prolongation at low heart rates in LQTS 3-specific, but not in wild-type iPS cell-derived cardiomyocytes. Hence, LQTS 3-specific cardiomyocytes can be purified from iPS cells with a lentiviral strategy, maintain the hallmarks of the LQTS 3 disease and can be used for automated electrophysiological characterization and drug screening. MDPI 2015-01-07 /pmc/articles/PMC4470242/ /pubmed/26237021 http://dx.doi.org/10.3390/jcm4010102 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Friedrichs, Stephanie Malan, Daniela Voss, Yvonne Sasse, Philipp Scalable Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral Purification Strategy |
title | Scalable Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral Purification Strategy |
title_full | Scalable Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral Purification Strategy |
title_fullStr | Scalable Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral Purification Strategy |
title_full_unstemmed | Scalable Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral Purification Strategy |
title_short | Scalable Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral Purification Strategy |
title_sort | scalable electrophysiological investigation of ips cell-derived cardiomyocytes obtained by a lentiviral purification strategy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470242/ https://www.ncbi.nlm.nih.gov/pubmed/26237021 http://dx.doi.org/10.3390/jcm4010102 |
work_keys_str_mv | AT friedrichsstephanie scalableelectrophysiologicalinvestigationofipscellderivedcardiomyocytesobtainedbyalentiviralpurificationstrategy AT malandaniela scalableelectrophysiologicalinvestigationofipscellderivedcardiomyocytesobtainedbyalentiviralpurificationstrategy AT vossyvonne scalableelectrophysiologicalinvestigationofipscellderivedcardiomyocytesobtainedbyalentiviralpurificationstrategy AT sassephilipp scalableelectrophysiologicalinvestigationofipscellderivedcardiomyocytesobtainedbyalentiviralpurificationstrategy |